Ipsen becomes the latest pharma to expand in Ireland, with a $50M investment in its facility in Dublin suburbs
It is no secret that Ireland has become a hot spot for pharma manufacturing projects over the past year, and it seems that Ipsen will be the latest player to get in on the action.
On Monday Ipsen unveiled the €52 million ($49.9 million) expansion it made into its active pharmaceutical ingredient manufacturing facility in Blanchardstown, a small suburb of Dublin. The investment is aimed at boosting medicine and ingredient production in cancer and rare disease space.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.